These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15325701)

  • 1. Molecular genetics and its clinical relevance.
    Stilgenbauer S; Döhner H
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):827-48, viii. PubMed ID: 15325701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
    Stilgenbauer S; Bullinger L; Lichter P; Döhner H;
    Leukemia; 2002 Jun; 16(6):993-1007. PubMed ID: 12040431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
    Kröber A; Bloehdorn J; Hafner S; Bühler A; Seiler T; Kienle D; Winkler D; Bangerter M; Schlenk RF; Benner A; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2006 Feb; 24(6):969-75. PubMed ID: 16418492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic prognostic markers.
    Stilgenbauer S; Döhner H
    Curr Top Microbiol Immunol; 2005; 294():147-64. PubMed ID: 16323431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.
    Kienle DL; Korz C; Hosch B; Benner A; Mertens D; Habermann A; Kröber A; Jäger U; Lichter P; Döhner H; Stilgenbauer S
    J Clin Oncol; 2005 Jun; 23(16):3780-92. PubMed ID: 15867199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic aberrations and survival in chronic lymphocytic leukemia.
    Döhner H; Stilgenbauer S; Benner A; Leupolt E; Kröber A; Bullinger L; Döhner K; Bentz M; Lichter P
    N Engl J Med; 2000 Dec; 343(26):1910-6. PubMed ID: 11136261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.
    Zenz T; Döhner H; Stilgenbauer S
    Best Pract Res Clin Haematol; 2007 Sep; 20(3):439-53. PubMed ID: 17707832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome.
    Tobin G; Thunberg U; Laurell A; Karlsson K; Aleskog A; Willander K; Söderberg O; Merup M; Vilpo J; Hultdin M; Sundström C; Roos G; Rosenquist R
    Haematologica; 2005 Apr; 90(4):465-9. PubMed ID: 15820941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
    Muñoz L; Lasa A; Carricondo MT; Hernández C; Ubeda J; Nomdedéu JF
    Cytometry B Clin Cytom; 2007 Mar; 72(2):96-102. PubMed ID: 17051526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis.
    Athanasiadou A; Stamatopoulos K; Tsompanakou A; Gaitatzi M; Kalogiannidis P; Anagnostopoulos A; Fassas A; Tsezou A
    Cancer Genet Cytogenet; 2006 Jul; 168(2):109-19. PubMed ID: 16843100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
    Mittal AK; Hegde GV; Aoun P; Bociek RG; Dave BJ; Joshi AD; Sanger WG; Weisenburger DD; Joshi SS
    Int J Mol Med; 2007 Oct; 20(4):461-9. PubMed ID: 17786276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
    Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
    Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia.
    Vasconcelos Y; Davi F; Levy V; Oppezzo P; Magnac C; Michel A; Yamamoto M; Pritsch O; Merle-Béral H; Maloum K; Ajchenbaum-Cymbalista F; Dighiero G
    J Clin Oncol; 2003 Nov; 21(21):3928-32. PubMed ID: 14581416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.
    Dickinson JD; Joshi A; Iqbal J; Sanger W; Bierman PJ; Joshi SS
    Int J Mol Med; 2006 May; 17(5):769-78. PubMed ID: 16596259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV.
    Valgañón M; Giraldo P; Agirre X; Larráyoz MJ; Rubio-Martinez A; Rubio-Felix D; Calasanz MJ; Odero MD
    Br J Haematol; 2005 Apr; 129(1):53-9. PubMed ID: 15801955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia.
    Aleskog A; Tobin G; Laurell A; Thunberg U; Lindhagen E; Roos G; Nilsson K; Nygren P; Sundström C; Höglund M; Larsson R; Rosenquist R
    Eur J Haematol; 2004 Dec; 73(6):407-11. PubMed ID: 15522062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
    Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
    Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of 5'IGH deletions in B-cell chronic lymphocytic leukemia.
    Quintero-Rivera F; Nooraie F; Rao PN
    Cancer Genet Cytogenet; 2009 Apr; 190(1):33-9. PubMed ID: 19264231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.